The endocannabinoid system (ECS) is possibly the most important physiological system in the development, maintenance and repair of the human body. Our principal aim is to identify a novel molecule, with appropriate physical, absorption, distribution, metabolic stability and excretion (ADME) properties that acts as a selective CB2R. An in silico screen was carried out mining our in-house library using a known CB2R agonist (HU-308) as a template. We aim to develop structure activity relationship to gain an understanding of the active site as no crystal structure of the CB2R exists. With over 100 synthesised compounds, good SAR has been established at various positions on our lead hit, high CB2R selectivity (>1000 fold) and activity (low nanomolar) has been achieved.      An in vivo assay has also been developed and provided evidence that our compounds are anti-inflammatory, we now aim to optimise parameters to a proof of principle compound for preferential administration methods.

Identification and optimisation of selective cannabinoid receptor 2 agonists

244th National Meeting (2012)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.